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ABSTRACT
Type 2 diabetes mellitus is an increasingly 
common medical problem for primary care 
clinicians to address. Treatment of diabetes has 
evolved from simple replacement of insulin 
(directly or through insulin secretagogs) 
through capture of mechanisms such as insulin 
sensitizers, alpha-glucosidase inhibitors, and 
incretins. Only very recently has recognition of 
the critical role of the gastrointestinal system as 
a major culprit in glucose dysregulation been 
established. Since glycated hemoglobin A1c 
reductions provide meaningful risk reduction as 
well as improved quality of life, it is worthwhile 
to explore evolving paths for more efficient use 
of the currently available pharmacotherapies. 
Because diabetes is a progressive disease, even 
transiently successful treatment will likely 
require augmentation as the disorder progresses. 
Pharmacotherapies with complementary 
mechanisms of action will be necessary to 
achieve glycemic goals. Hence, clinicians 
need to be well informed about the various 
noninsulin alternatives that have been shown to 
be successful in glycemic goal attainment. This 
article reviews the benefits of glucose control, 
the current status of diabetes control, pertinent 
pathophysiology, available pharmacological 
classes for combination, limitations of current 
therapies, and suggestions for appropriate 
combination therapies, including specific 
suggestions for thresholds at which different 
strategies might be most effectively utilized by 
primary care clinicians. 
Keywords: DPP-4 inhibitor; exenatide; 
liraglutide; metformin; primary care; sitagliptin; 
thiazolidinedione; type 2 diabetes
INTRODUCTION
Globally, the World Health Organization (WHO) 
reports that as many as 220 million individuals 
have diabetes.1 The Framingham Offspring Study 
Enhanced content for this article is 
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database indicates that the incidence of type 2 
diabetes mellitus (DM2) has doubled in the US 
from the 1970s through the 1990s.2 In the US, 
it was estimated in 2010 that nearly 26 million 
individuals had diabetes, of which 7.0 million 
(27%) were undiagnosed.3 Furthermore, the 
prevalence of diabetes (driven largely by DM2) is 
projected to reach 12.0% by 2050, affecting more 
than 48 million individuals.4 Disconcertingly, 
almost half of deaths in this population occur 
before the age of 70 years, and the WHO 
projects that the number of diabetes deaths will 
double between 2005 and 2030. Clinicians also 
increasingly recognize the additional burden of 
DM2 in children and adolescents.5 Most patients 
with DM2 are appropriately managed within the 
primary care sector, with the occasional need for 
consultation by diabetologists.
Since DM2 is associated with increased 
mortality, increased risk of macrovascular disease 
(ie, stroke and myocardial infarction), and 
increased microvascular disease (ie, retinopathy, 
nephropathy, and neuropathy), there are 
numerous challenges worthy of intervention 
for risk reduction. Healthy diet, regular physical 
activity, maintaining a normal body weight, and 
avoiding tobacco use can prevent or delay the 
onset of diabetes. 
Good control of glucose (glycated hemoglobin 
A1c  [HbA1c] <7%) in patients with DM2 has been 
shown to reduce microvascular disease and 
improve quality of life.6 Despite the salutary 
effects attributable to good glucose control, only 
about half of patients with diabetes are at the 
currently recognized treatment goal.7 In addition 
to glycemic control, comprehensive DM2 care 
requires attention to blood pressure, lipids, and 
lifestyle factors (ie, diet, exercise, and abstinence 
from smoking), leading to complex medication 
and lifestyle treatment regimens. Failure to attain 
glycemic goals may reflect the competing demands 
of attaining multiple goals at the same time.
Currently, the most widely recognized 
measure for glycemic control is HbA1c, 
although exceptions, such as for persons with 
hemoglobinopathy, do exist. Recommendations 
from the American Diabetes Association (ADA) 
suggest an HbA1c goal <7.0%.6 Ultimately, as 
diabetes progresses, most patients will require 
insulin therapy. However, the purpose of this 
communication is to focus upon ways primarily 
to capitalize on non-insulin combination 
therapies to achieve glycemic goals.
Guidelines from the European Association 
for the Study of Diabetes (EASD) concur with 
the concept that utilization of polypharmacy, 
especially early combination therapy, 
is one of the greatest advances in DM2 
disease management.8 Skillful application of 
combination treatments will be necessary to 
attain and maintain adequate glucose control 
in the majority of DM2 patients.9 For diabetic 
patients who “deselect” injection therapy 
(ie, those who are unwilling or unable to use 
parenteral treatments), it will be particularly 
necessary to capitalize upon the complementary 
therapeutic effects of multiple oral agents.
CONCERNS ABOUT THE CURRENT 
STATUS OF DIABETES CONTROL
The current status of diabetes control is far 
from optimal. According to the most recent 
National Health and Nutrition Examination 
Survey (NHANES) data, between 2003 and 2006 
only 57.1% of adults with diabetes surveyed 
had achieved the recommended HbA1c target 
of 7.0% or lower.7 Other surveys have shown 
that 30% or more patients with diabetes have 
an HbA1c greater than 8.0%.10,11 The complexity 
of multifaceted goal achievement is perhaps 
best reflected by 2003-2006 data from NHANES 
that showed the dismally low composite of only 
12.2% of patients with diabetes achieving all 164 Diabetes Ther (2011)  2(3):162-177.
three primary goals for HbA1c (<7.0%), blood 
pressure (<130/80 mm Hg), and low-density 
lipoprotein cholesterol (<100 mg/dL).7
Additionally, despite consistent confirmation 
of treatment benefits, clinicians have been 
historically somewhat sluggish in advancement 
of pharmacotherapy to attain appropriate 
glucose goals. In a 2000-2002 study of 
30 academic primary care and diabetes/
endocrinology clinics in the US, among patients 
with HbA1c values above goal only 40.4% had 
their current treatment regimens adjusted at 
the most recent clinic visit.12 Similarly, a study 
from Kaiser Permanente (Northwest) data from 
1994-2002 demonstrated that patients may not 
receive appropriate augmentation of therapy 
promptly: among patients on metformin 
monotherapy (n=354), the average amount of 
time between their first HbA1c reading >8.0% 
and treatment augmentation or substitution 
was 14 months; for patients on sulfonylurea 
monotherapy (n=2517), the average duration was 
20 months.13 Thus, there remains a great, unmet 
need for prompt and effective intensification of 
diabetes management. Early combination therapy 
offers promise in this regard. 
 Recognizing that many patients with DM2 
languish for protracted periods with glucose 
levels well above the recognized toxic threshold, 
the most recent ADA/EASD algorithm has 
provided a pathway for more prompt control 
of hyperglycemia by indicating the propriety 
of introducing insulin as an early agent in 
combination therapy with metformin to 
achieve glucose management goals.14 We do not 
dispute the advantages of prompt control or 
the efficiency of goal attainment with insulin. 
Rather, we see great opportunity for improved 
recognition of the prompt glycemic control 
that can be attained with skillful combination 
of non-insulin therapies, and advancement of 
therapy with greater chronological alacrity. 
Treatment advancement typically relies upon 
measurement of HbA1c. Although long-term 
management is appropriately directed by 
HbA1c, initial management, rapid advancement 
of pharmacotherapy requires monitoring of 
fasting glucose status, which can reflect day-to-
day changes in control, versus the 90-120-day 
control window provided by A1c monitoring. 
As discussed below, most currently available 
agents achieve as much as 80% or more of 
their potential to lower fasting glucose within 
4 weeks of initiation. Waiting to advance therapy 
beyond that interval suggests lack of awareness 
of the time course of action of therapy. 
Additionally, Monnier et al.15 (Figure 1) 
have shown that in most newly diagnosed 
patients with DM2 (particularly when HbA1c
Figure 1. Relative contributions of postprandial 
and fasting hyperglycemia (%) to the overall diurnal 
hyperglycemia over quintiles of glycated hemoglobin A1C 
(HbA1c).15 Adapted with permission from Diabetes Care 
2003;26:881-885. Reproduced with permission from the 
American Diabetes Association. a=Significant difference 
was observed between fasting and postprandial plasma 
glucose (paired t test). b=Significantly different from 
all other quintiles (analysis of variance [ANOVA]). 
c=Significantly different from quintile 5 (ANOVA). 
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is >7.3%), it is the fasting glucose component 
of dysglycemia that is the primary contributor 
to elevated HbA1c. Hence, we believe in a “fix 
the fasting first” philosophy when addressing 
most individuals with hyperglycemia. Although 
there is a linear relationship between HbA1c and 
adverse outcomes, recent literature (notably 
from the Action to Control Cardiovascular 
Risk in Diabetes16 [ACCORD] study) has 
challenged the concept that lower is always 
better. In ACCORD, patients randomized 
to tight control (HbA1c <6.0%) had worse 
cardiovascular outcomes than those randomized 
to “traditional” therapy.16 The ADA 2011 
position statement reiterates that HbA1c goals 
must be individualized.17 Considerations for 
individualization include age, health status, 
comorbidities, regimen complexity, body 
habitus, economic issues, duration of diabetes, 
presence of known cardiovascular disease, 
microvascular complications, hypoglycemia 
awareness, and personal health preferences.17
Indeed, there are some circumstances 
where prudence would argue against tight 
control. For instance, persons with a history of 
severe hypoglycemia may be at risk for further 
recurrences. If a patient has hypoglycemia 
unawareness, glucose levels may progress to 
precariously low levels before characteristic 
symptoms emerge to stimulate correction, 
placing the patient at substantial risk. Similarly, 
medications that mask or blunt physiological 
responses to hypoglycemia (eg, beta-blockers 
and alpha-beta-blockers) may augment risk. In 
any of these circumstances, clinicians would be 
wise to avoid overly tight control.
BENEFITS OF GLYCEMIC CONTROL
In the UK Prospective Diabetes Study (UKPDS),33
the composite endpoint of “any diabetes-
related endpoint” was reduced by 12% for an 
achieved HbA1c of 7.0% (intensive treatment 
group) versus 7.9% (conventional treatment 
group), microvascular endpoints (retinopathy, 
nephropathy, neuropathy) were reduced by 
25%, and there was also a decrease in need for 
laser treatments and cataract surgery.18 These 
beneficial effects were seen without distinction 
as to which category of pharmacotherapy 
was used; that is, no demonstrable difference 
in endpoint reduction among sulfonylurea, 
insulin, or metformin was noted in the overall 
population studied. In addition to microvascular 
treatment benefits seen in UKPDS, long-term 
observation of the cohort showed what has 
been termed the “legacy effect”: favorable effects 
years after conclusion of the trial. After 10 years 
of post-trial monitoring, the group that had 
received intensive treatment originally showed 
reductions in any diabetes-related endpoint, 
microvascular disease, myocardial infarction, 
and all-cause mortality; these favorable results 
were found despite the fact that by the end 
of this observation period, HbA1c levels in 
the group originally assigned to intensive 
treatment were essentially the same as the group 
originally assigned to conventional treatment.19
Another important trial that showed benefits 
of glucose control in DM2 was the Kumamoto 
study.20 In a population of 110 Japanese DM2 
patients, retinopathy was reduced by 69% and 
nephropathy by 70% after 6 years of intensive 
glucose control to an HbA1c level of 7.1%.20
One of the often neglected benefits of good 
glucose control is the effect upon quality 
of life. Although motivation for patients to 
adhere to medication regimens may spring 
from a desire to avoid microvascular and 
macrovascular consequences, patients who feel 
better are directly rewarded for their efforts. 
In a randomized, double-blind study of DM2 
patients (n=569), subjects were assigned to 
active treatment (sulfonylurea) or placebo for 166 Diabetes Ther (2011)  2(3):162-177.
12 weeks, at which point numerous quality of life 
endpoints were compared.21 Symptom distress, 
general perceived health, cognitive functioning, 
and overall visual analog scale improved in the 
treatment group, but worsened in the placebo 
group. Active treatment also had an impact on 
the number of work days missed. In their zeal to 
prevent “hard” endpoints, clinicians should not 
lose sight of the benefits on quality of life that 
may be achieved through good glucose control.
RELEVANT PATHOPHYSIOLOGY 
DM2 is a progressive disorder; it appears that 
once beta-cell loss begins, the process continues 
indefinitely.22 We know of no therapy that has 
been shown to meaningfully attenuate this 
progressive loss in humans. The progressive 
nature of diabetes necessitates that clinicians 
become familiar with complementary therapies 
that are necessary as the disease progresses.
DM2 is considered an “ecogenic” disorder, 
meaning that both genetic and lifestyle factors 
are involved. Pathogenic defects involved in 
glucose dysregulation include the pancreas 
(alpha and beta cells), the gastrointestinal 
tract, liver, skeletal muscle, and adipose tissue. 
Stressors, such as infection or injury, that 
activate counter-regulatory hormones (cortisone 
and epinephrine) may also contribute to glucose 
dysregulation (see ADA Position Statement23).
Multiple pathologies are associated with 
diabetes, foremost of which (at least initially), 
appears to be insulin resistance.24 As much as 
a decade before fasting or postprandial glucose 
becomes elevated (Figure 2), insulin resistance 
may be present. As long as increased beta-cell 
activity compensates for this insulin resistance, 
no derangement of fasting or postprandial 
glucose is evident. 
It has been reported that by the time a 
diagnosis of DM2 has been made, 50% of 
beta-cell function has been lost.26 At this point, 
insufficient insulin is available to counteract 
insulin resistance, and suprathreshold glucose 
levels (postprandial and/or fasting) emerge. It 
is obvious that diabetic dysfunction occurs well 
before we make the clinical diagnosis, because 
as many as 50% of DM2 patients already have 
one or more diabetic complications the day the 
diagnosis is made.27
Insulin resistance occurs in multiple tissue 
compartments: the skeletal muscle, liver, and 
adipose compartment all exhibit insulin resistance 
leading to both hyperglycemia and dyslipidemia. 
It is not surprising, therefore, that multiple 
therapies will be needed to address multiple 
pathophysiological defects. For instance, the 
gastrointestinal tract is increasingly recognized 
as a critical organ in glucose metabolism. The 
incretin class of agents, currently comprising the 
glucagon-like peptide-1 (GLP-1) receptor agonists, 
such as exenatide and liraglutide, and dipeptidyl 
peptidase-4 (DPP-4) inhibitors, such as sitagliptin, 
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saxagliptin, and linagliptin, harnesses the 
capacity of GLP-1 to modulate glucose. Indeed, it 
has been suggested that more than 50% of meal-
stimulated insulin production is attributable to 
intestinal incretins.28
Another gastrointestinal-related phenomenon 
in diabetes is the absence of first-phase insulin 
secretion.29 In healthy individuals, a dietary 
glucose load is met with an almost immediate 
insulin response known as first-phase insulin 
release; this prompt response by preformed 
insulin keeps pace with rapidly rising glycemia. 
Due to the absence of first-phase insulin release 
(typical of DM2), rapidly rising glucose levels are 
unmet and result in inappropriate tissue exposure 
to elevated glucose. Alpha-glucosidase inhibitors 
help to address this pathophysiological defect by 
slowing glucose absorption, incretins do so by 
delaying gastric emptying, and a low glycemic 
index diet addresses this defect by selecting foods 
that produce a less rapid rise in glucose levels.
Pancreatic alpha-cell dysfunction compounds 
the problems of hyperglycemia. Supranormal 
glucose levels in healthy individuals suppress 
glucagon production by alpha cells, yet 
diabetic patients demonstrate continued 
glucagon production, even in the presence of 
hyperglycemia. In response to hyperglycemia, 
rising insulin levels should shut down hepatic 
glycogenolysis. However, since the liver is 
also insulin resistant, it does not respond 
appropriately to insulin levels, and continues 
to produce glucose despite hyperglycemia. 
Incretins suppress excess glucagon production. 
Although insulin resistance is the pathological 
defect with which clinicians are most familiar, 
it should be clear from the discussion above 
that incretin pathways, particularly as related 
to glucagon dysregulation, also offer an 
opportunity for modulation of a fundamental 
pathophysiological defect in DM2.
PHARMACOLOGICAL CATEGORIES 
Many therapeutic choices exist, which allows 
individualized intervention by selecting 
medications that work in a complementary 
fashion to address the various pathophysiological 
defects of DM2. Currently available antidiabetic 
medications are broadly classified into four 
mechanistic groups: insulin enhancers, insulin 
sensitizers, hepatic modulators, and intestinal 
Table 1. Mechanisms of action of commonly used antidiabetic medications. 14
Drugs
Increased 
insulin
Insulin 
resistance
Hepatic glucose 
metabolism
Intestinal glucose 
absorption/regulation
Alpha-glucosidase 
inhibitors
X
Metformin X X
Sulfonylureas X
Glinides X
Thiazolidinediones X X
GLP-1 R analogs X X X
DPP-4 inhibitors X X X
DPP-4=dipeptidyl peptidase-4; GLP-1 R=glucagon-like peptide-4 receptor.168 Diabetes Ther (2011)  2(3):162-177.
regulators (Table 1). Combination therapies 
should employ agents with complementary 
mechanisms. There is no suggestion that 
using two agents with similar mechanisms (eg, 
sulfonylurea plus a glinide) will be beneficial.
Tolerability 
Any choice of therapy should, of course, include 
considerations of tolerability. The most common 
factors that limit acceptability are weight gain 
and hypoglycemia. To ensure adherence and 
success in goal attainment, clinicians should 
routinely advance therapy in a method that 
minimizes risk of hypoglycemia, as well as 
providing clear advice about management 
of hypoglycemia, should it occur. Finally, 
consistent enquiry about medication-induced 
adverse effects that might limit compliance 
should be routine.
MANAGEMENT OF DIABETES
Pharmacotherapy for dysglycemia is only one 
limb of the treatment approach. All persons 
with DM2 will require lifestyle changes, periodic 
monitoring of cardiovascular risk factors 
(lipids, glucose, and blood pressure), attention 
to target-organ damage (renal-function, 
ophthalmological-function, and nerve-function 
monitoring), and a long-term relationship with 
healthcare professionals; therefore, we do not 
wish to oversimplify care of diabetes to just 
glucose control. That being said, skillful control 
of glucose is a cornerstone of comprehensive 
therapy. Unfortunately, monotherapy has 
distinct limitations for most patients.
Limitations of Current Monotherapies
Monotherapy is unlikely to maintain adequate 
control in DM2 over the long term. This does 
not necessarily reflect inadequacy of the 
pharmacotherapy, but instead may reflect several 
other factors. First, DM2 is a progressive disease 
and no treatment has been convincingly shown 
to retard this loss of function. As can be seen in 
Figure 3, all four treatment choices in the UKPDS 
(diet, metformin, sulfonylurea, and insulin) were 
associated with progressive loss of HbA1c control 
despite titration.32 After 3 years on treatment, 
only 45% of patients remained at target HbA1c, 
and by 6 years, only 30% of those receiving 
monotherapy were at goal.31 Hence, clinicians 
must become aware of the essential inevitability 
of polypharmacy for glucose control in patients 
with DM2. Second, many persons become more 
sedentary as they age because of the combined 
effects of social phenomena, comorbidities such 
as osteoarthritis, and some diabetes-induced 
disabilities (eg, diabetic peripheral neuropathic 
pain). Third, common comorbidities, such as 
hypertension, may be treated with medications 
that worsen glucose control (eg, diuretics and 
beta-blockers). Finally, patient “fatigue” (less 
Figure 3. Median glycated hemoglobin A1C (HbA1c) 
levels in cohorts of patients followed up to 10 years by 
assigned treatment in the UK Prospective Diabetes Study 
(UKPDS) 34.30 Figure adapted with permission from 
DeFronzo et al., Annals of Internal Medicine; 1999. Table 
inset from Turner et al.31 
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enthusiasm over long periods of time) may 
foster poor adherence. 
There are limited data to inform clinicians 
about durability of monotherapy. The A Diabetes 
Outcome Progression Trial9 (ADOPT) compared 
long-term monotherapy with rosiglitazone, 
metformin, or glyburide in recently diagnosed 
DM2 patients (n=4360) with reference to 
their ability to maintain a fasting glucose 
<180 mg/dL. At 5 years, the rosiglitazone group 
failure rate (15%) was lower than the sulfonylurea 
(34%) and metformin (21%) treatment groups. 
This is the only long-term treatment trial of its 
type, but lends credence, along with the UKPDS, to 
the concept that monotherapy is not sustainable 
in the majority of patients over the long term. 
One of the inherent limitations of any 
monotherapy (except insulin) is that there 
is a ceiling, or maximum, potential effect on 
HbA1c. Mean reductions in HbA1c with any 
monotherapy are rarely greater than 2.0% 
(0.5% to 1.5%), depending upon the agent and 
initial HbA1c level (Table 2).33 Hence, monotherapy 
for a patient who is newly diagnosed with DM2 
and presents with an HbA1c >9.0% is unlikely to 
attain an HbA1c goal <7.0%; as the presenting 
HbA1c increases further, HbA1c goal attainment 
becomes progressively less likely. 
Combination Therapy
At the current time, an agent of any one 
of the classes of pharmacotherapy may be 
rationally combined with any other. Exceptions 
include combining glinides (nateglinide, 
repaglinide) with sulfonylureas, which both 
work by essentially identical methods, so their 
combination would not be rational (no greater 
effect would be anticipated). Similarly, use 
of two agents from the incretin class (GLP-1 
receptor analogs and DPP-4 inhibitors) would 
not be complementary, and would not be 
Table 2. Comparison of clinical profiles of common antidiabetic medications.
Drug
Mean HbA1c 
reduction
Time to achieve maximum 
therapeutic benefit, weeks
Limitations
Common adverse 
events >80% 100%
Metformin 1.0% to 2.0% 4 <9 Renal failure, 
CHF
GI side effects
Sulfonylurea (eg, glipizide 
GITS)
1.0% to 2.0% Approximately 6 Approximately 8 Renal, hepatic Hypoglycemia
Glinide (eg, nateglinide) 1.0% to 2.0% Approximately 3 4 Three or four times 
a day dosing
Hypoglycemia
Alpha-glucosidase inhibitor 0.5% to 0.8% - - None GI side effects
Thiazolidinedione (eg, 
pioglitazone)
0.5% to 1.0% 6 14 Severe CHF, 
weight gain
Weight gain
DPP-4 inhibitors 0.5% to 0.8% 3 6 Renal disease
Exenatide 1.0% to 2.0% 3 4 Renal disease Nausea
Liraglutide 0.5% to 1.1% 2 4 -
CHF=chronic heart failure; DPP-4=dipeptidyl peptidase-4; GI=gastrointestinal; GITS=gastrointestinal therapeutic system.
Based on Kuritzky et al.33170 Diabetes Ther (2011)  2(3):162-177.
expected to have an enhanced effect. Although 
disputed by some, the preponderance of expert 
opinion suggests that the combination of any 
insulin secretagogue with insulin is not rational 
polypharmacy.14 With those exceptions, agents 
from any other classes may be successfully 
combined. Choice of therapeutic agent should 
be influenced by the level of HbA1c elevation. For 
simplification purposes pertinent to the majority 
of patients seen in the primary care setting, we 
stratify diabetic control by HbA1c level: stage 1 
(HbA1c 6.5% to 8.4%), stage 2 (HbA1c 8.5% to 
9.4%), and stage 3 (HbA1c >9.5%) (Figure 4). 
This approach is based on the concepts explored 
by Nathan et al. in the ADA/EASD consensus 
statement.14
Lifestyle is at the foundation of all 
treatment regimens and may alone reduce 
HbA1c as much as 2.9%. This potential efficacy 
notwithstanding, the majority of patients 
with lifestyle modification will still require 
adjunctive monotherapy to control HbA1c even 
at stage 1; unless a specific contraindication 
exists, metformin should be a therapeutic 
component at all steps of treatment. At stage 
2, we believe it is unlikely that HbA1c will be 
sufficiently controlled with monotherapy 
(metformin), so combination therapy should 
be considered routinely. With metformin as 
the foundation, a second agent (at lowest dose) 
may be initiated concomitantly, titrating the 
dose as often as every 4 weeks. As Table 2 shows, 
80% or more of drug efficacy is measurable 
within that interval (with the exception 
of thiazolidinediones, which may require 
6-8 weeks to attain a similar magnitude of 
efficacy).35,36 In a meta-analysis of randomized 
controlled trials of at least 3 months duration 
evaluating the addition of non-insulin 
antidiabetic drugs to maximal stable metformin 
therapy, all classes of agent were associated with 
similar significant reductions in HbA1c versus 
placebo and were significantly more likely to 
achieve HbA1c goal than placebo (Table 3).37
We disagree with the most recent American 
Association of Clinical Endocrinologists (AACE) 
guideline that suggests combination therapy as 
the initial step for persons with HbA1c 7.0% to 
8.0%,38 noting that a substantial component of 
this population (especially those at the lower 
end of this range) will be able to attain goal 
with one of the more potent agents; a similar 
approach (initial monotherapy with metformin, 
for instance) is supported in the most recent 
ADA/EASD position paper.14 Utilization of 
polypharmacy prior to maximizing glycemic 
control with well chosen monotherapy seems, 
to us, overtreatment at stage 1 and exposes 
the patient to unnecessary expense, potential 
adverse effect profile, complexity, and risk for 
hypoglycemia.
Stage 2 HbA1c levels can occasionally be 
controlled with monotherapy, but most 
Figure 4. Suggested treatment algorithm for patients with 
type 2 diabetes mellitus, according to glycated hemoglobin 
A1C (HbA1c) level at presentation. Treatment should be 
adjusted every 4 weeks (6–8 weeks for thiazolidinediones 
[TZDs]) based upon degree of fasting blood glucose 
(FBG) attained.14 Adjust dosage q4w* based upon degree 
of FBG reduction attained.
*q6-8w for TZDs.
Lifestyle   diet   exercise
Symptomatic?
Stage 1
HbA1c 6.5-8.4
Stage 2
HbA1c 8.5-9.4
Stage 3
HbA1c ≥9.5
Metformin Metformin +
2nd agent
Triple combination
or
metformin + insulin
NO
Insulin
YESDiabetes Ther (2011)  2(3):162-177. 171
individuals at stage 2, and essentially all persons 
at stage 3, merit initiation of combination 
therapy at the outset, since no monotherapy 
(insulin excepted) has a significant likelihood 
of attaining its goal.39,40 Indeed, at stage 3 it 
is likely that triple therapy will be necessary, 
although occasionally, metformin combined 
with fully titrated insulin may achieve its 
goal.41 For symptomatic patients at any stage 
of diabetes or during acute metabolic stress (eg, 
infection or surgery), consideration of insulin to 
correct the typical large excursions of glucose is 
appropriate. Often, after a period of stabilization 
in these patients, a return to oral therapy may be 
more convenient. As mentioned above, patient 
preferences should also ultimately shape the 
therapeutic plan.
The ADA/EASD algorithm for the metabolic 
management of DM2 (Figure 5) supports initial 
treatment of DM2 with metformin, in the 
absence of contraindications.14 All other classes 
of pharmacotherapy are complementary to 
metformin. Choice of the next agent will largely 
depend upon the above-mentioned factors, 
because there is a paucity of well controlled 
clinical trials that directly compare different 
diabetes treatment regimens.14 As mentioned 
earlier, a recent meta-analysis of antidiabetic 
agents combined with metformin demonstrated 
similar HbA1c reductions with all classes of 
agents, but differences in their associations 
with weight gain and risk of hypoglycemia.37
The combination with which clinicians have 
the most familiarity is probably metformin plus 
a sulfonylurea. The use of this combination 
is reflected in a 29-week study42 comparing 
monotherapy with glyburide or metformin 
versus glyburide plus metformin. The results 
showed the combination provided near maximal 
reduction in fasting glucose within 5 weeks, 
amounting to an 80-mg/dL greater reduction 
than either monotherapy.42 A longer-term study, 
the PRESERVE-Beta trial,43 assessed the effects 
of glyburide or nateglinide plus metformin 
Table 3. Results of a meta-analysis of randomized controlled trials comparing the efficacy of noninsulin antidiabetic 
drugs when added to metformin therapy in patients with type 2 diabetes not controlled by metformin alone. Adapted with 
permission from Phung et al. JAMA 2010;303:1410-1418.37 Copyright © 2010 American Medical Association. All rights reserved.
Percentage change in HbA1c HbA1c goal achieved
Group vs. placebo  No. of trials WMD (95% CI)
No. of 
trials RR (95% CI)
All drugs 20 −0.79 (−0.90, −0.68)* 10 2.56 (1.99, 3.28)†
Sulfonylureas 3 −0.79 (−1.15, −0.43)* 1 3.38 (2.02, 5.83)
Glinides 2 −0.71 (−1.24, −0.18) 1 3.20 (1.47, 7.58)
Thiazolidinediones 3 −1.00 (−1.62, −0.38)† 1 1.69 (1.24, 2.33)
AGIs 2 −0.65 (−1.11, −0.19) 0 NA
DPP-4 inhibitors 8 −0.79 (−0.94, −0.63)† 6 2.44 (1.78, 3.33)†
GLP-1 analogs 2 −0.99 (−1.19, −0.78) 1 3.96 (2.37, 6.79)
*I2≥75%
†I2=50% to 75%
AGIs=α-glucosidase inhibitors; DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1; HbA1c=hemoglobin A1c; 
NA=not applicable; RR=relative risk; WMD=weighted mean difference.172 Diabetes Ther (2011)  2(3):162-177.
in 428 treatment-naïve patients with DM2 over 
2 years. In patients treated with glyburide/
metformin, HbA1c was reduced from 8.3% to 
6.9% after 104 weeks, whereas nateglinide/
metformin treatment reduced HbA1c from 8.4% 
to 6.9 % (P<0.0001 vs. baseline for both groups), 
demonstrating that good glycemic control 
can be maintained for 2 years with either 
treatment regimen.43
In a 6-month study of DM2 patients 
(n=701) whose baseline HbA1c was 8.0% while 
on metformin (ie, the preferred initial oral 
monotherapy in DM2 as per the 2009 ADA/
EASD algorithm14), subjects were randomized 
to placebo or sitagliptin 100 mg once daily.44
By the end of the trial, mean HbA1c was 7.26% 
in the DPP-4 inhibitor group versus 7.95% in 
the placebo group. Another study evaluating 
Figure 5. American Diabetes Association and the European Association for the Study of Diabetes (ADA/EASD) consensus 
algorithm for the metabolic management of type 2 diabetes. Reinforce lifestyle interventions at every visit and check glycated 
hemoglobin A1c (HbA1c) every 3 months until HbA1c is <7% and then at least every 6 months. The interventions should be 
changed if HbA1c is ≥7%.14 aSulfonylureas other than glibenclamide (glyburide) or chlorpropamide. bInsufficient clinical use to be 
confident regarding safety. CHF=congestive heart failure; GLP-1=glucagon-like peptide-1. Copyright 2009 American Diabetes 
Association. From Diabetes Care 2009;32:193-203. Reproduced with permission from the American Diabetes Association. 
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a combination of metformin plus a DPP-4 
inhibitor assessed sitagliptin (100 mg once daily 
or 50 mg twice daily) and metformin (500 or 
1000 mg twice daily) alone and in combination 
in 1091 DM2 patients with mean baseline 
HbA1c 8.8%.45 Adding sitagliptin 50 mg twice 
daily to metformin 500 mg twice daily provided 
another 0.6% HbA1c reduction compared with 
metformin alone. Similarly, adding sitagliptin 
50 mg twice daily to metformin 1000 mg 
twice daily provided an additional 0.8% HbA1c
reduction compared with metformin alone. 
Two 52-week studies assessed the efficacy 
and safety of two other DPP-4 inhibitors, 
vildagliptin46 and saxagliptin,47 in patients with 
DM2 inadequately controlled with metformin. 
Results of these trials demonstrated that 
addition of a DPP-4 inhibitor to a metformin 
regimen resulted in HbA1c reductions 
comparable to those with glicazide plus 
metformin46 or glipizide plus metformin,47 with 
the added advantage of fewer hypoglycemic 
events, and either weight loss or no weight gain. 
Thus, the currently available DPP-4 inhibitors 
have more in common with each other than 
dissimilarities between them. Efficacy of HbA1c
reduction, safety, and tolerability appear 
comparable for the three currently available 
DPP-4 inhibitors. A Canadian trial conducted 
in 16 clinics assembled 200 DM2 patients 
with HbA1c ≥8.5% despite being on maximally 
tolerated doses of metformin and a sulfonylurea 
(mean baseline HbA1c was 9.7%).41 The ADA/
EASD 2009 algorithm identifies metformin 
plus a sulfonylurea as a well validated step-
two combination.14 It is not uncommon 
for clinicians to choose oral triple-therapy 
combinations, despite the lack of support 
that a third oral agent could bring patients 
from so high an HbA1c (9.7%) down to goal 
(<7.0%). Indeed, at the end of the trial, only 
14% of subjects who had a thiazolidinedione 
(troglitazone) added to their existing 
sulfonylurea/metformin regimen achieved an 
HbA1c <7.0%.41
This communication has focused primarily 
upon skillful combinations of non-insulin tools. 
Nonetheless, sometimes, insulin is a preferred 
choice, especially when combination therapy is 
likely to consist of three or more agents or when 
patients are symptomatic. Rather than trying to 
achieve control with three oral agents, earlier 
addition of basal insulin (ie, neutral protamine 
hagedorn [NPH], detemir, or glargine) or incretin 
mimetic (exenatide, liraglutide) is much more 
likely to attain an HbA1c goal <7.0%. The Treat-
to-Target Trial48 compared insulin glargine and 
NPH administered once nightly in 756 DM2 
subjects with an HbA1c >7.5% who were receiving 
one or two oral agents. After 18 weeks, the mean 
HbA1c in both groups had dropped to 7.0%. The 
frequency of hypoglycemia was significantly 
greater in the group that received NPH, but both 
agents were equally successful in reaching the 
HbA1c goal (<7.0%).
The DURATION-2 trial,49 a 26-week double-
blind randomized study, assessed the efficacy 
and safety of exenatide once weekly (n=170) 
versus sitagliptin (n=172) or pioglitazone 
(n=172) in metformin-treated patients. At the 
end of the study, HbA1c levels were reduced 
significantly more by exenatide (7.2%) than 
with sitagliptin (7.7%) or pioglitazone (7.4%); 
treatment differences were –0.6 for exenatide 
versus sitagliptin (P<0.0001) and –0.3 for 
exenatide versus pioglitazone (P=0.0165). 
Also, in a double-blind, placebo-controlled 
study in 733 patients treated with metformin 
and a sulfonylurea, exenatide-treated patients 
were more likely to achieve HbA1c levels ≤7% 
than placebo-treated subjects (exenatide 
10 µg, 34% and 5 µg, 27%, placebo, 9%; both 
doses of exenatide P<0.0001).50 Liraglutide, 
the latest GLP-1 agonist to come to the US 174 Diabetes Ther (2011)  2(3):162-177.
market, was evaluated in a series of phase 3 
trials (Liraglutide Effect and Action in Diabetes 
[LEAD]);51-54 liraglutide therapy resulted in an 
average HbA1c level reduction of 1.18% across 
all trials.
CONCLUSIONS
Skillful management of DM2 requires 
attention to multiple paths of dysfunction, 
with particular regard for lifestyle modulation, 
glucose control, cardiovascular risk factor 
reduction, and respect for the complexity 
such a diverse disorder places before our 
patients. Microvascular toxicity (retinopathy, 
nephropathy, and neuropathy) is reduced by 
good glucose control; hence, prompt glycemic 
goal attainment should be a compelling 
agenda. Combination therapy is an appropriate 
tool to maximize success in glucose control. 
Historically, sluggishness to advance treatment 
in a timely fashion despite inadequate goal 
attainment (commonly called “clinical 
inertia”), contributed to by both clinicians 
and patients alike, has been commonplace 
in DM2 patients. The plentiful and diverse 
tools available for good glucose control allow 
rational combinations to promptly gain 
control of dysglycemia. Lack of awareness of 
the timecourse of action of therapeutic agents 
may have limited the briskness with which 
clinicians titrate dosage. We hope that the 
instructive tables and diagrams depicting the 
typical timecourse of efficacy for available 
agents will be instrumental in addressing 
previous obstacles to prompt goal attainment. 
Consistent goal attainment can be enhanced 
by awareness of the pertinent physiological 
derangements attendant to DM2. Skillful 
combination of pharmacotherapies is intended 
to reduce risk for target organ damage and 
improve the quality of our patients’ lives.
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